Ryutaro Wakayama

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Astellas Pharma Gmbh, Yamanouchi Pharmaceutical Company Ltd.. Active years: 2005-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryutaro Wakayama. Retrieved from https://idiyas.com/inventor/ryutaro-wakayama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 57.1

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 38(Granted Patents)

Location History:

Tsukuba, JP (2005 - 2009)
Tokyo, JP (2011 - 2014)

Company Filing History:

Yamanouchi Pharmaceutical Company Ltd.

patents

Years Active: 2005-2014

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8765764 - 2-acylaminothiazole derivative or salt thereof (2014-07-01),

2. 8338429 - 2-acylaminothiazole derivative or salt thereof (2012-12-25),

3. 7973078 - Sulfonamide compound or salt thereof (2011-07-05),

4. 7638536 - 2-Acylaminothiazole derivative or salt thereof (2009-12-29),

5. 7569688 - Propane-1, 3-dione derivative (2009-08-04),

6. 7056910 - 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof (2006-06-06),

7. 6960591 - Propane-1,3-dione derivative (2005-11-01),

Title: The Innovations of Ryutaro Wakayama

Introduction

Ryutaro Wakayama is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that aid in treating thrombocytopenia. With a total of seven patents to his name, his work has had a considerable impact on medical science.

Latest Patents

Wakayama's latest patents include a 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof. This compound exhibits an excellent effect of proliferating human c-mpl-Ba/F3 cells and has the activity of increasing platelets. It promotes the formation of megakaryocytic colonies, making it a valuable asset in treating thrombocytopenia. The innovative nature of this compound highlights Wakayama's commitment to advancing medical treatments.

Career Highlights

Throughout his career, Ryutaro Wakayama has worked with prominent companies in the pharmaceutical industry. He has been associated with Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research.

Collaborations

Wakayama has collaborated with esteemed colleagues such as Keizo Sugasawa and Susumu Watanuki. These partnerships have fostered an environment of innovation and have led to the successful development of his patented compounds.

Conclusion

Ryutaro Wakayama's contributions to the field of pharmaceuticals through his innovative patents and collaborations demonstrate his dedication to improving medical treatments. His work continues to influence the industry and offers hope for patients suffering from thrombocytopenia.

Profile summary based on public USPTO records.